One to Watch: Veradermics Raises $150M in Series C Financing; Shares Positive Preliminary Phase 2 Data for Oral Minoxidil in Pattern Hair Loss
Veradermics has completed an oversubscribed $150 million Series C financing. The financing was designed to support the registrational development and planned New Drug Application (“NDA”) submission for Veradermics’ lead investigational product, VDPHL01, the potential first and only extended-release oral minoxidil treatment designed specifically for hair regrowth in women and men. In related news, preliminary data […]